MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Publications Digest. In a recent publication, Carbonneil et al. analyzed the key stages of health technologies reimbursement in France, outlining the process from regulatory authorization to health technology assessment and final reimbursement decision.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its EU HTA Publications Digest. In a recent publication, Willemsen et al. analyzed the Dutch response to the EU Health Technology Assessment Regulation (HTAR), which took effect in January 2025.

In July 2025, the National Institute for Health and Care Excellence (NICE) published one new Interventional Procedures Guidance on pulsed-field ablation in atrial fibrillation, one new Early Value Assessment on digital technologies in anxiety and depression, and two new Late Stage Assessments (One-piece closed bags for colostomies, intermittent urethral catheters for chronic incomplete bladder emptying).

In July 2025, the Dutch Healthcare Institute (ZIN) announced a new policy framework “Reimbursement within Research” (Vergoeding in Onderzoek), which allows temporary reimbursement under basic health insurance during the evaluation period for specialist medical care and medical devices with limited evidence of effectiveness. ZIN is currently reviewing the framework to provide advice on implementation. The launch of the new framework is expected in November 2025.

In July 2025, the Belgian National Institute for Health and Disability Insurance (INAMI/RIZIV) updated the list of reimbursable companion diagnostics to be used from August 1, 2025. One new predictive biomarker – analysis of BRAF V600 mutation status in glioma – was added to the list.

On July 16, 2025, the UK Government published the Life Sciences Sector Plan, which outlines targeted actions to support world-class research and development, attract investment, and accelerate health innovation and NHS reform. The key actions to ensure faster access to clinically and cost-effective technologies include implementing the Rules-Based Pathway for MedTech, “Innovator Passport”, national standard guidance on value-based procurement for MedTech, and “HealthStore” (coverage of approved health apps for patients).

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Sustainability Publications Digest. In a recent publication, Davies et al. systematically reviewed implementation approaches to improve environmental sustainability in operating theatres.

On July 15, 2025, the Ministry of Labor, Health, Solidarity, and Families published the instruction on the application for coverage with evidence development programs for 2025-2026. The instruction details the specific fields of research, the application procedures, and the deadlines for different types of programs (PHRC, PRME, PREPS, PHRIP, and PRT).

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Health Economic Publications Digest. In a recent publication, Yan et al. systematically reviewed statistical approaches used to analyze EQ-5D outcomes in randomized clinical trials worldwide.

Our goal at MTRC is to inform the decision-making of our clients and to support their market access activities. Below is a snapshot of our planned activities for the next two weeks. This can help our existing and prospective clients to understand the potential scope of our support better. From the week of July 28th, we plan to work on 16 projects. Review the complete list of planned activities in this post.

On July 15, 2025, the Austrian Institute for HTA (AIHTA) published four new HTAs (decision support documents) and two updates to previous decision support documents that provide recommendations regarding possible inclusion of new procedures in the reimbursement catalog of individual medical services (MEL). The assessments concerned cardiovascular, gastrointestinal, interventional radiology, men's health, urology, and orthopedics fields.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Publications Digest. In a recent publication, Williams et al. compared the authorization and reimbursement processes for two novel cardiovascular devices (Watchman and Impella) in the US, Canada, the UK, and the Netherlands.